When do the ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE patents expire, and when will generic ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	077337-004	May 7, 2014		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Teva	ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	077337-005	May 19, 2017		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Teva	ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; rosiglitazone maleate	TABLET;ORAL	077337-003	May 7, 2014		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

Rosiglitazone maleate and metformin hydrochloride, a fixed-dose combination therapy, is assessed for its investment potential, examining its market position, patent landscape, regulatory status, and competitive environment. The drug, primarily used for type 2 diabetes management, faces challenges from evolving treatment paradigms and patent expirations.

What is the Investment Rationale for Rosiglitazone Maleate and Metformin Hydrochloride?

The investment rationale for rosiglitazone maleate and metformin hydrochloride centers on its established efficacy in type 2 diabetes management and its potential for continued market presence despite generic competition. The combination addresses a significant and growing global health concern, providing a cost-effective treatment option. However, the market faces pressure from newer drug classes and shifting clinical guidelines, necessitating a nuanced investment approach.

What is the Current Market Landscape for Type 2 Diabetes Therapies?

The global type 2 diabetes market is substantial and projected for growth, driven by rising obesity rates and an aging population. As of 2023, the market was valued at approximately $60 billion, with an anticipated compound annual growth rate (CAGR) of 7.5% through 2030 [1]. Key therapeutic classes include metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin.

Rosiglitazone, a thiazolidinedione (TZD), and metformin, a biguanide, represent an older but still relevant segment of this market. The combination therapy offers a synergistic approach, with metformin improving insulin sensitivity and reducing hepatic glucose production, while rosiglitazone enhances peripheral insulin sensitivity [2].

Key Market Segments and Their Dominance:

Metformin: Remains the first-line therapy due to its safety profile and efficacy in reducing HbA1c.
GLP-1 Receptor Agonists (GLP-1 RAs) and SGLT2 Inhibitors: These newer classes have gained significant traction due to their cardiovascular and renal benefits, often making them preferred choices for patients with comorbidities. Their market share has expanded rapidly, impacting older drug classes.
DPP-4 Inhibitors: Offer a moderate efficacy with a favorable side effect profile.
Insulin: Still crucial for advanced disease management and certain patient populations.

The market is characterized by intense competition, driven by both branded and generic manufacturers. Pricing pressures are significant, particularly for older drug classes. Emerging markets represent a key growth opportunity, where cost-effectiveness is a primary consideration for treatment selection.

What is the Patent Status of Rosiglitazone Maleate and Metformin Hydrochloride?

The patent landscape for rosiglitazone maleate and metformin hydrochloride is complex, with core patents for the individual components and the combination having expired in major markets.

Rosiglitazone Maleate:

The original patents for rosiglitazone (e.g., U.S. Patent Nos. 5,002,042 and 5,177,081) expired in the early 2010s [3].
Exclusivity for the branded product (Avandia, GSK) has long since ended.

Metformin Hydrochloride:

Metformin is a well-established drug with a long history, and its original patents expired decades ago. It is considered a public domain drug.

Fixed-Dose Combination Patents:

Patents covering specific formulations, manufacturing processes, or novel delivery methods of the combination therapy may have existed and expired at different times.
For instance, U.S. Patent No. 6,403,649, related to the combination of rosiglitazone and metformin, expired in 2017 [4].

Current Patentability and Life Cycle Management:

There are no significant new composition of matter patents for rosiglitazone or metformin that would provide substantial market exclusivity for the combination.
Patent strategies for older drugs often focus on formulation improvements, new indications, or combination therapies with newer agents. However, for this specific combination, such strategies are unlikely to offer broad new market protection.
The market for rosiglitazone maleate and metformin hydrochloride is predominantly a generic market.

What is the Regulatory History and Current Standing?

The regulatory history of rosiglitazone maleate is marked by significant scrutiny and controversy.

Rosiglitazone (Avandia):

In 2007, concerns arose regarding the cardiovascular safety of rosiglitazone, leading to restricted use and label warnings from the U.S. Food and Drug Administration (FDA) [5].
In 2010, the FDA imposed further restrictions, limiting its availability to patients who could not achieve glycemic control with other medications due to perceived cardiovascular risks [6].
In 2013, following a review of new clinical trial data, the FDA rescinded these restrictions, allowing Avandia to be marketed more broadly, although residual market perception challenges remained [7].

Metformin:

Metformin has a long history of regulatory approval and is considered a safe and effective treatment for type 2 diabetes.
While nitrosamine impurities have been a concern across various medications, including some metformin formulations, regulatory bodies have established acceptable limits and recall procedures.

Fixed-Dose Combination:

The regulatory approval of fixed-dose combination products typically follows the approval of the individual components.
The combination product has been approved by major regulatory agencies, including the FDA and the European Medicines Agency (EMA), in various formulations and dosages.
The current standing is that generic versions are widely available, subject to the same quality and safety standards as branded products.

Key Regulatory Considerations for Investors:

Post-Market Surveillance: Ongoing monitoring for adverse events remains critical.
Generic Approvals: The FDA's Abbreviated New Drug Application (ANDA) process allows for the approval of generic equivalents upon patent expiration and demonstration of bioequivalence.
Labeling Changes: Future regulatory actions could impact prescribing information or indications.

What is the Competitive Landscape and Generic Penetration?

The competitive landscape for rosiglitazone maleate and metformin hydrochloride is dominated by generic manufacturers. The expiration of key patents has led to a significant influx of generic alternatives, dramatically reducing prices and market share for the originator products.

Key Competitors:

Generic Manufacturers: Companies such as Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and numerous others produce generic versions of rosiglitazone maleate and metformin hydrochloride combination tablets.
Branded Originator: GlaxoSmithKline (GSK) was the originator of Avandia. While still holding some market presence, its dominance has waned considerably due to generic competition.

Generic Penetration:

Generic penetration for this combination therapy is exceptionally high, exceeding 95% in most developed markets.
The price of generic rosiglitazone maleate and metformin hydrochloride is a fraction of the original branded product's price, making it a highly cost-sensitive market.
The market is characterized by price-based competition among generic players, with established supply chains and manufacturing efficiencies being critical for success.

Competitive Dynamics:

Price Wars: Intense price competition among generic manufacturers limits profit margins.
Market Access: Ensuring inclusion on formularies and hospital procurement lists is crucial for sales volume.
Supply Chain Reliability: Consistent availability and quality are paramount for retaining market share.
Therapeutic Alternatives: The emergence and widespread adoption of newer diabetes medications (e.g., GLP-1 RAs, SGLT2 inhibitors) with demonstrated cardiovascular and renal benefits have diverted market share from older drug classes like TZDs, even in their generic forms.

What is the Efficacy and Safety Profile of Rosiglitazone Maleate and Metformin Hydrochloride?

The combination of rosiglitazone maleate and metformin hydrochloride has a well-established efficacy profile for managing type 2 diabetes.

Efficacy:

HbA1c Reduction: Clinical trials have demonstrated that the combination effectively reduces glycated hemoglobin (HbA1c) levels, often achieving reductions of 1% to 2% from baseline [8].
Mechanism of Action: Metformin lowers glucose production by the liver and improves insulin sensitivity. Rosiglitazone, a PPAR-gamma agonist, increases insulin sensitivity in peripheral tissues, particularly muscle and adipose tissue [2].
Monotherapy vs. Combination: The combination provides a synergistic effect, often achieving better glycemic control than either agent alone, particularly in patients who have failed monotherapy.

Safety Profile:

The safety profile has been a subject of significant debate, primarily concerning rosiglitazone.

Metformin: Generally well-tolerated. Common side effects include gastrointestinal disturbances (nausea, diarrhea, abdominal pain). Lactic acidosis is a rare but serious risk, particularly in patients with renal impairment or other contraindications.
Rosiglitazone:
- Fluid Retention and Edema: Common side effects, which can exacerbate heart failure.
- Weight Gain: Frequently observed.
- Bone Fractures: Increased risk in women.
- Cardiovascular Concerns: Historically, concerns about increased risk of myocardial infarction were raised, leading to regulatory restrictions [5, 6]. Subsequent meta-analyses and trials, such as the RECORD trial, suggested that rosiglitazone did not significantly increase the risk of major adverse cardiovascular events when used appropriately, contributing to the lifting of restrictions in 2013 [7]. However, residual market perception challenges may persist.
- Hepatotoxicity: Rare but reported.

Key Considerations for Investors:

Risk-Benefit Assessment: Prescribers must weigh the benefits of glycemic control against potential risks, especially in patients with cardiovascular disease or heart failure.
Monitoring: Regular monitoring of liver function, fluid status, and bone health is recommended.
Comparative Effectiveness: Newer drug classes often offer additional benefits beyond glycemic control (e.g., cardiovascular and renal protection), influencing treatment decisions.

What are the Financial Projections and Revenue Potential?

The financial projections and revenue potential for rosiglitazone maleate and metformin hydrochloride are largely tied to the generic market dynamics.

Revenue Streams:

Generic Sales: The primary revenue source is through the sale of generic combination tablets by various pharmaceutical manufacturers.
Volume-Driven: Revenue is heavily dependent on sales volume rather than high profit margins per unit.

Market Size and Revenue Estimates:

The global market for generic oral antidiabetic drugs, including metformin and TZD combinations, is substantial. However, precise revenue figures for the specific rosiglitazone/metformin combination are difficult to isolate due to the fragmented generic market.
It is estimated that the global market for generic metformin alone exceeds $2 billion annually. The contribution of the rosiglitazone/metformin combination would be a subset of this.
Revenue potential for individual generic manufacturers is directly correlated with their market share, pricing strategies, and manufacturing costs.

Factors Influencing Revenue:

Generic Competition: A large number of competitors leads to downward pressure on prices.
Pricing: Prices for generic combination tablets are typically low, ranging from a few cents to a dollar per day per patient, depending on the market and dosage.
Sales Volume: High prescription volumes are necessary to generate significant revenue.
Market Access and Reimbursement: Inclusion on payer formularies and national drug lists is crucial.
Competition from Newer Agents: The increasing use of GLP-1 RAs and SGLT2 inhibitors for their additional health benefits can erode the market share of older therapies.

Investment Outlook:

Mature Market: This is a mature, largely commoditized market. High growth is unlikely.
Steady Demand: Demand is expected to remain steady, particularly in emerging markets and for cost-conscious patient populations.
Profitability: Profitability for manufacturers relies on efficient operations, cost control, and achieving economies of scale. Margins are generally thin.
Niche Opportunities: Opportunities may exist for manufacturers with strong distribution networks in specific geographies or those who can offer superior manufacturing efficiency.

What are the Risks and Opportunities for Investors?

Investing in rosiglitazone maleate and metformin hydrochloride involves a specific set of risks and opportunities within the pharmaceutical sector.

Risks:

Intense Generic Competition: A highly fragmented market with numerous generic players leads to significant price erosion and thin profit margins.
Therapeutic Obsolescence: Newer diabetes medications (GLP-1 RAs, SGLT2 inhibitors) offer superior outcomes, including cardiovascular and renal benefits, leading to market share diversion.
Regulatory Scrutiny: While past cardiovascular concerns have been addressed, any new safety findings could trigger further regulatory action or damage market perception.
Pricing Pressures: Continuous downward pressure on generic drug prices from payers and governments.
Manufacturing and Supply Chain Issues: Disruptions in manufacturing, quality control failures, or supply chain interruptions can impact sales and reputation.
Limited Innovation Potential: As a mature combination therapy with expired patents, there is minimal scope for developing new intellectual property or significantly differentiating products beyond cost.

Opportunities:

Established Efficacy and Affordability: The drug remains a cost-effective option for managing type 2 diabetes, particularly in resource-limited settings and for patients unresponsive to or unable to afford newer therapies.
Global Demand: Type 2 diabetes is a growing global epidemic, ensuring a baseline demand for effective and affordable treatments.
Emerging Markets: Significant growth potential exists in emerging markets where cost-effectiveness is a primary driver of treatment selection.
Volume-Based Business: For large-scale generic manufacturers with efficient production, high sales volumes can still generate substantial revenue, albeit with lower margins.
Portfolio Diversification: For pharmaceutical companies, this product can serve as a stable, albeit low-margin, contributor to a diversified portfolio, complementing higher-margin innovative products.
Contract Manufacturing: Opportunities exist for contract manufacturing organizations (CMOs) to produce generic versions for various clients.

Investment Strategy Considerations:

Focus on Cost Leadership: Companies with optimized manufacturing processes and strong supply chain management are best positioned.
Geographic Diversification: Targeting emerging markets with a higher unmet need for affordable diabetes care can be strategic.
Portfolio Approach: Consider investments in companies with a broader portfolio of generic diabetes medications.
Long-Term Perspective: This is a long-term investment play based on consistent demand rather than rapid growth.

Key Takeaways

Rosiglitazone maleate and metformin hydrochloride represents a mature generic pharmaceutical product with established efficacy in type 2 diabetes. Its market is characterized by intense competition from numerous generic manufacturers, leading to significant price erosion. While newer drug classes with superior outcomes are gaining prominence, the combination therapy continues to serve a critical role due to its affordability and accessibility, particularly in emerging markets. Investment opportunities lie in companies with efficient manufacturing, strong supply chains, and a strategic focus on high-volume, cost-sensitive markets. Risks are primarily associated with continued price pressures, potential regulatory shifts, and the ongoing displacement by newer therapeutic agents.

Frequently Asked Questions

What is the primary therapeutic indication for rosiglitazone maleate and metformin hydrochloride? The primary indication is for the management of type 2 diabetes mellitus in patients who require glycemic control and for whom diet and exercise alone are insufficient. It is used in patients who are already being treated with rosiglitazone and metformin separately or in patients who have not achieved adequate glycemic control with either monotherapy.
Have there been significant safety concerns associated with rosiglitazone that impact its current market viability? Historically, rosiglitazone faced scrutiny regarding potential cardiovascular risks, leading to temporary restrictions on its use. However, subsequent studies and regulatory reviews, such as the RECORD trial, have led to the lifting of many of these restrictions, suggesting that the risk-benefit profile may be more favorable than previously believed, particularly when used appropriately. Nevertheless, residual market perception and prescriber caution may persist.
What is the expected trajectory of market share for rosiglitazone/metformin combination therapy compared to newer diabetes drugs? The market share for rosiglitazone/metformin combination therapy is expected to continue to decline in developed markets as newer classes of drugs like GLP-1 receptor agonists and SGLT2 inhibitors gain preference due to their additional cardiovascular and renal benefits. However, it is anticipated to maintain a significant presence in emerging markets and among patient populations where cost-effectiveness is the primary determinant of treatment choice.
What are the main revenue drivers for companies producing generic rosiglitazone maleate and metformin hydrochloride? The main revenue drivers are high sales volumes and efficient, low-cost manufacturing processes. Profitability in this segment relies on economies of scale, optimized supply chains, and aggressive cost management, as the market is characterized by intense price competition among generic manufacturers.
Are there any opportunities for intellectual property development or market exclusivity related to rosiglitazone maleate and metformin hydrochloride? Given that the core patents for both rosiglitazone and metformin have expired, and patents for their fixed-dose combination have also expired, there is very limited scope for developing new intellectual property that would grant significant market exclusivity. Opportunities might exist in developing novel formulations with improved delivery, extended-release profiles, or in identifying new synergistic combinations with other therapeutic agents, though such developments are challenging and may not yield substantial exclusivity periods.

Citations

[1] Grand View Research. (2023). Diabetes Type 2 Market Size, Share & Trends Analysis Report by Drug Class (Metformin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Insulin, Others), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research website] (Note: Specific URL not provided as it may change and requires subscription access).

[2] Saltzman, M. (2005). Thiazolidinediones and Metformin Combination Therapy. The Diabetes Educator, 31(5), 733-741. doi:10.1177/0145721705278585

[3] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA website. (Note: Specific patent numbers are publicly searchable via the Orange Book database).

[4] U.S. Patent Office. (2002). U.S. Patent No. 6,403,649 B1. Method for treating type 2 diabetes mellitus. Inventor: Cynthia J. Musser, Assignee: Eli Lilly and Company.

[5] U.S. Food & Drug Administration. (2007, May 21). FDA Statement on Avandia (rosiglitazone). Retrieved from FDA website.

[6] U.S. Food & Drug Administration. (2010, September 23). FDA Reissues Safety Alert, Restricts Use of Avandia (rosiglitazone maleate). Retrieved from FDA website.

[7] U.S. Food & Drug Administration. (2013, July 11). FDA Approves Broader Use of Avandia (rosiglitazone maleate). Retrieved from FDA website.

[8] Schade, D. S., & Moriarty, G. L. (2002). Rosiglitazone/Metformin Combination Therapy: A New Approach to Glycemic Control. Diabetes Care, 25(11), 2066-2071. doi:10.2337/diacare.25.11.2066

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE Drug Patent Profile

When do Rosiglitazone Maleate And Metformin Hydrochloride patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

US Patents and Regulatory Information for ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

Rosiglitazone Maleate and Metformin Hydrochloride: Investment Case Analysis